Get the Stockscreener App
5.76
3.97%
0.22
Olema Pharmaceuticals Inc stock is traded at $5.76, with a volume of 432.64K.
It is up +3.97% in the last 24 hours and up +26.87% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$5.54
Open:
$5.56
24h Volume:
432.64K
Relative Volume:
0.65
Market Cap:
$395.33M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-2.6791
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+4.54%
1M Performance:
+26.87%
6M Performance:
+15.43%
1Y Performance:
-50.04%
1-Day Range:
$5.56
$5.9718
1-Week Range:
$5.34
$5.9718
52-Week Range:
$2.86
$13.93
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
5.76 | 395.33M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Published on: 2025-08-20 21:48:05 - Newser
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Breast Cancer Drug Developer Olema Oncology Set for 5 Major Healthcare Conference Appearances in September - Stock Titan
Published on: 2025-08-20 14:18:04 - Newser
Is Olema Pharmaceuticals Inc. in Accumulation Phase Now2025 Technical Overview & Expert Approved Momentum Trade Ideas - newsyoung.net
Applying sector rotation models to Olema Pharmaceuticals Inc.Price Action & Stepwise Entry/Exit Trade Alerts - Newser
JPMorgan Chase & Co. Increases Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $29.00 - MarketBeat
What’s next for Olema Pharmaceuticals Inc. stock priceBond Market & Entry Point Confirmation Signals - Newser
Order flow analysis tools used on Olema Pharmaceuticals Inc.Market Growth Summary & AI Driven Stock Movement Reports - Newser
Measuring Olema Pharmaceuticals Inc.’s beta against major indicesCPI Data & Proven Capital Preservation Methods - Newser
Is Olema Pharmaceuticals Inc. stock poised for growthIndex Update & Risk Controlled Daily Trade Plans - Newser
What institutional flow reveals about Olema Pharmaceuticals Inc.July 2025 Levels & Weekly High Momentum Picks - Newser
Analysts Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $24.00 - MarketBeat
How high can Olema Pharmaceuticals Inc. stock goJuly 2025 Spike Watch & Growth Focused Stock Reports - Newser
Is it too late to sell Olema Pharmaceuticals Inc.Weekly Stock Report & Fast Moving Trade Plans - Newser
Applying big data sentiment scoring on Olema Pharmaceuticals Inc.Portfolio Value Summary & Low Volatility Stock Suggestions - Newser
What recovery options are there for Olema Pharmaceuticals Inc.July 2025 Rallies & Daily Price Action Insights - Newser
What high frequency data says about Olema Pharmaceuticals Inc.2025 Market WrapUp & Expert Approved Trade Ideas - Newser
Published on: 2025-08-19 03:58:55 - newsyoung.net
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $24.00 Average PT from Analysts - Defense World
Combining price and volume data for Olema Pharmaceuticals Inc.Trade Ideas & Low Risk Investment Opportunities - Newser
Does Olema Pharmaceuticals Inc. qualify in momentum factor screeningInflation Watch & Expert Approved Trade Ideas - Newser
Momentum divergence signals in Olema Pharmaceuticals Inc. chartJuly 2025 Final Week & Real-Time Volume Spike Alerts - Newser
Key metrics from Olema Pharmaceuticals Inc.’s quarterly dataJobs Report & Weekly High Potential Stock Alerts - Newser
Olema Pharmaceuticals (NASDAQ:OLMA) Given New $21.00 Price Target at Citigroup - MarketBeat
Is a relief rally coming for Olema Pharmaceuticals Inc. holders2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
What moving averages say about Olema Pharmaceuticals Inc.2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser
Identifying reversal signals in Olema Pharmaceuticals Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - Newser
Volatility clustering patterns for Olema Pharmaceuticals Inc.2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Olema Pharmaceuticals (NASDAQ:OLMA) Issues Quarterly Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Olema Pharmaceuticals Inc Stock (OLMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Graham G. Walmsley | Director |
Dec 17 '24 |
Sale |
6.75 |
700,761 |
4,730,137 |
0 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER |
Dec 16 '24 |
Option Exercise |
4.87 |
14,000 |
68,180 |
129,509 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):